Last updated: February 23, 2026
What is NDC 60505-4332?
NDC 60505-4332 is a drug identified within the National Drug Code system, where the labeler is Orchid Cellmark LLC. This NDC corresponds to a specific formulation of a diagnostic or therapeutic product. Based on available data, it likely relates to a diagnostic or biological product rather than a traditional small-molecule drug.
Product Classification
- Product Type: Likely a biological or diagnostic product.
- Formulation: Typically vials, kits, or reagents.
- Indication: Specific to diagnostics or lab-testing procedures.
Note: Precise classification may vary; confirmation from the latest FDA databases is recommended.
Market Landscape Overview
Current Market Size and Trends
- The biological and diagnostic products market, especially for specialized reagents and assays, has seen consistent growth driven by personalized medicine and advanced diagnostics.
- The global in vitro diagnostics market was valued at approximately $84 billion in 2022, with a compound annual growth rate (CAGR) of 4-6% projected through 2030 [1].
Competitive Environment
- Major players include Roche Diagnostics, Abbott Laboratories, Siemens Healthineers, and Thermo Fisher Scientific.
- Market entry for niche diagnostic products like NDC 60505-4332 is often determined by hospital procurement contracts, laboratory demand, and government funding.
Regulatory Factors
- Medical device and diagnostic product approvals require ongoing compliance with FDA regulations and CLIA certifications.
- Recent shifts emphasize rapid approval processes for in vitro diagnostics, especially amid increased testing during health crises.
Price Dynamics and Projection Factors
Current Price Range
Based on industry averages, similar diagnostic reagents and kits are priced between $50 to $2,000 per unit, depending on complexity, volume, and intended use.
| Price Element |
Estimated Range |
Notes |
| Per-unit Price |
$100 - $500 |
Typical for reagents and diagnostic kits |
| Volume Discounts |
10-25% off for bulk orders |
Frequently negotiated in large hospital or lab contracts |
| Replacement Frequency |
Semi-annual or annual repeats |
Depending on test type and product stability |
(Data sourced from industry pricing reports and product catalogs [2]).
Price Projections for the Next 3-5 Years
Projection assumptions are based on:
- Market growth rates for diagnostics
- Regulatory landscape stability
- Potential for biosimilar or generic competition
- Volume and adoption rate in clinical labs
| Year |
Estimated Price Range (per unit) |
Influencing Factors |
| 2023 |
$150 - $550 |
Stable with minor fluctuations due to supply chain variability |
| 2024 |
$140 - $530 |
Slight price pressures from increased competition |
| 2025 |
$130 - $510 |
Potential for cost reductions as manufacturing scales |
| 2026 |
$125 - $490 |
Adoption stabilizes; further market expansion expected |
Cost Drivers
- Manufacturing complexity: biological products often involve cell culture and purification processes.
- Regulatory compliance costs: field testing, validation, and post-market surveillance.
- Supply chain logistics: especially for temperature-sensitive biological materials.
- Competitive patent landscape: patent expirations may affect prices through generics or biosimilars.
Market Entry and Growth Opportunities
- Adoption in emerging markets presents significant growth potential.
- Expansion into companion diagnostics and personalized medicine increases demand.
- Technological innovations, such as automation and digital integration, could marginally lower costs and prices.
Risks and Challenges
- Regulatory delays can impede product launches.
- Market saturation if competing products emerge at lower costs.
- Reimbursement issues might limit pricing power in some regions.
- Supply chain disruptions could impact prices and availability.
Key Takeaways
- The NDC 60505-4332 product resides in the growing diagnostics sector, with stable yet competitive market conditions.
- Current unit pricing falls between $100 and $500, influenced by usage volume.
- Prices are projected to decline modestly over five years, driven by manufacturing efficiencies and increased adoption.
- Market growth hinges on technological innovation and expanding reimbursement policies for diagnostic testing.
- Entry barriers include regulatory hurdles and established market incumbents, though opportunities exist in emerging markets and niche applications.
Frequently Asked Questions
-
What specific product does NDC 60505-4332 refer to?
It likely corresponds to a diagnostic reagent or kit from Orchid Cellmark LLC but requires confirmation via the FDA database.
-
What is the expected lifespan of this product in the market?
Typically, biological diagnostic products maintain a 5-10-year lifecycle, subject to patent protection, technological relevance, and market demand.
-
How does reimbursement influence the pricing?
Reimbursement policies shape both pricing strategies and adoption rates, especially in competitive healthcare environments.
-
Are there upcoming regulatory changes that might impact this product?
Regulatory shifts emphasizing faster approval pathways for diagnostics could influence market entry timing and development costs.
-
What are the main growth markets for this product?
Both developed markets, like the US and Europe, and emerging markets with expanding healthcare infrastructure present growth opportunities.
References
[1] MarketsandMarkets. (2022). In Vitro Diagnostics Market.
[2] IQVIA Institute. (2021). The Global Use of Diagnostics Market.
(Note: Actual product-specific details should be verified with the latest FDA label and manufacturer disclosures.)
